Get the Stockscreener App
2.20
10.55%
0.21
Pre-market:
2.19
-0.01
-0.45%
Naya Biosciences Inc stock is traded at $2.20, with a volume of 64,875.
It is up +10.55% in the last 24 hours and down -50.45% over the past month.
See More
Previous Close:
$1.99
Open:
$2.1105
24h Volume:
64,875
Relative Volume:
2.44
Market Cap:
$1.18M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-11.29%
1M Performance:
-50.45%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.0091
$2.28
1-Week Range:
$1.80
$2.4699
52-Week Range:
$1.80
$12.48
Naya Biosciences Inc Stock (NAYA) Company Profile
Name
Naya Biosciences Inc
Sector
Industry
Phone
(978) 878-9505
Address
5582 BROADCAST COURT, SARASOTA
Compare NAYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAYA
Naya Biosciences Inc
|
2.20 | 1.18M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Naya Biosciences Inc Stock (NAYA) Latest News
NAYA Biosciences Delays 2024 Yearly Report Filing - TipRanks
Bifunction conjunction afoot; multiple players competing - BioWorld MedTech
NAYA Biosciences to effect 1-for-12 reverse split - TipRanks
NAYA Biosciences announces 1-for-12 reverse stock split By Investing.com - Investing.com Australia
NAYA Biosciences announces 1-for-12 reverse stock split - Investing.com India
NAYA Biosciences Announces 1-for-12 Reverse Stock Split Effective March 18, 2025 - Nasdaq
NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025 - GlobeNewswire
NAYA stock touches 52-week low at $0.33 amid market challenges - Investing.com
NAYA Biosciences Supports U.S. Executive Order to Increase Access and Affordability of IVF Services - Nasdaq
NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment - The Manila Times
NAYA Biosciences nominates five candidates for the Board - TipRanks
NAYA Biosciences Announces Nomination of New Board Members - GlobeNewswire
Maxim Group Upgrades NAYA Biosciences (NAYA) - MSN
NAYA Stock Hits 52-Week Low at $0.35 Amid Market Challenges - MSN
NAYA Biosciences (NASDAQ:NAYA) Raised to Buy at Maxim Group - Defense World
NAYA Biosciences Raises $9.5M Amid Nasdaq Compliance Issues - TipRanks
NAYA Biosciences sets public offering at $0.70 per unit By Investing.com - Investing.com South Africa
Lakewood Ranch life sciences firm seeks to raise $9.5M through public offering - Business Observer
NAYA Stock Hits 52-Week Low at $0.62 Amid Market Challenges - Investing.com
NAYA Biosciences Announces Pricing of $9.5 Million Public Offering - GlobeNewswire
NAYA Biosciences sets public offering at $0.70 per unit - Investing.com
NAYA Biosciences Raises $9.5M in Public Offering to Fund Acquisition and Growth Plans - StockTitan
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
NAYA Biosciences expands oncology pipeline with new antibody By Investing.com - Investing.com Nigeria
NAYA Biosciences expands oncology pipeline with new antibody - Investing.com
NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody - GlobeNewswire
NAYA Biosciences Unveils NY-500, AI-Enhanced Cancer Antibody Outperforming Keytruda - StockTitan
NAYA (NAYA Biosciences) Long-Term Debt & Capital Lease Obli - GuruFocus.com
The horror of Saydnaya jail, symbol of Assad excesses - News- Graphic
INVO Bioscience : Expands its Presence in Eurasia with New Distribution Agreements to Commercialize the INVOcell In Vivo Fertilization System - Marketscreener.com
NAYA Biosciences files to sell $10M of units - Nasdaq
Grapevine December 15, 2024: Changing of the guard - The Jerusalem Post
NAYA Biosciences Inc. (NAYA) reports earnings - Quartz
NAYA (NAYA Biosciences) Profitability Rank : 2 (As of Jun. 2024) - GuruFocus.com
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
NAYA Biosciences to Present Translational Insights to - GlobeNewswire
NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewswire
INVO Bioscience, Inc. announced that it has received $0.275 million in funding - Marketscreener.com
INVO Bioscience Closes Wisconsin Fertility Institute Acquisition - Marketscreener.com
INVO Bioscience Closes Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel Invocell System for Use in the Treatment of Infertility - Marketscreener.com
INVO Bioscience, Inc. Announces Appointment of Pressly Ahammed as Director of International Business Development - Marketscreener.com
INVOcell Appoints Yve Lyppens as Director Business Development Asia Pacific - Marketscreener.com
INVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com
INVO Bioscience, Inc. Announces Grand Opening of "Positib Fertility, an INVO Center" in Monterrey, Mexico on November 1, 2021 - Marketscreener.com
INVO Bioscience Announces the Appointment of Steve Shum as Chief Executive Officer - Marketscreener.com
NAYA Biosciences Announces Initiation of Phase 1/2a - GlobeNewswire
NAYA (NAYA Biosciences) Enterprise Value : $15.50 Mil (As of Oct. 25, 2024) - GuruFocus.com
Top Premarket Gainers - Marketscreener.com
NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma - The Manila Times
The court declared bankruptcy of MPG AgroProduction OÜ - The Manila Times
INVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 - Marketscreener.com
Naya Biosciences Inc Stock (NAYA) Financials Data
There is no financial data for Naya Biosciences Inc (NAYA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):